According to legislation.gov.uk, the Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 were made on 9 June 2026, laid before Parliament on 10 June 2026 and will come into force on 1 July 2026. The measure amends the 2018 rules that govern payments from certain manufacturers and suppliers of branded medicines used by the health service. For the sector, this is less about headline politics and more about the percentage applied to net sales income. That percentage feeds directly into revenue retention, margin planning and cash flow for businesses supplying branded medicines into NHS channels.

The regulations extend across England and Wales, Scotland and Northern Ireland. Under the statutory scheme, qualifying companies make payments to the Secretary of State based on net sales income, or estimated net sales income, from branded health service medicines. That means a technical change in a statutory instrument can have a very real effect on finance teams. Even when unit demand is unchanged, the share of sales income handed back to government can move sharply, and that changes second-half forecasting.

The key amendment is the update to payment percentages for 2026 and later applicable periods. The explanatory note says manufacturers or suppliers that paid the higher 24.3% rate on supplies in the first half of 2026 will move to a reduced 8.7% rate from 1 July 2026 to 31 December 2026. Crucially, the note says that 8.7% applies instead of the 16.5% rate that would otherwise have been used under the table in regulation 3(1). In plain English, eligible firms get a materially lighter charge in the second half because they were already charged more heavily in the first six months.

For branded pharmaceutical manufacturers, that creates an immediate earnings read-across. A fall from 24.3% to 8.7% does not change the top line generated by NHS sales, but it should improve the proportion retained after scheme payments, all else being equal. Suppliers with heavy NHS exposure may therefore see a cleaner second-half profile than the first-half rate alone would have suggested. The detail matters most for businesses sitting in the statutory scheme, where a few percentage points can make a visible difference to operating margins.

There is also a practical accounting point. Because the new rate starts on 1 July 2026, finance teams will need to revisit accruals, full-year assumptions and guidance language where these payments are material. For investors and lenders, the regulation is a reminder that NHS-facing drug revenues cannot be read in isolation. Net sales income may be stable, but the cash ultimately kept by the manufacturer depends in part on how the payment scheme is calibrated across the year.

The instrument was signed by Preet Kaur Gill, Parliamentary Under-Secretary of State at the Department of Health and Social Care, and the department says an impact assessment has been prepared and is available via legislation.gov.uk. That suggests the government sees this as a measured adjustment within an existing set of rules, rather than a wholesale rewrite of the branded medicines regime. Still, mid-year percentage changes are rarely trivial for the companies affected. Procurement volumes may grab the headlines, but payment mechanics often tell the more useful story for shareholders and management teams.

The broader message for the market is straightforward. This amendment does not remove pricing pressure from the NHS supply chain, but it does reset the near-term burden for eligible branded medicines suppliers after a steep first half. From a Market Pulse UK view, the regulation matters because it sits where healthcare policy meets company economics. From 1 July 2026, the question for affected drugmakers is not whether demand exists, but how much of each pound of branded NHS sales they are now able to retain.